Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $78.70 USD
Change Today -0.30 / -0.38%
Volume 1.3M
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ENDO INTERNATIONAL PLC (ENDP) in the last 6 months

Announced 05/18/15
10.39B for Par Pharmaceutical Holdings, Inc.
Merger/Acquisition

Endo International plc (NASDAQ:ENDP; TSX:ENL) entered into a definitive agreement to acquire Par Pharmaceutical Holdings, Inc. from TPG Global, LLC, TPG Biotechnology Partners IV, L.P. and others for $8 billion in cash and stock on May 18, 2015. Endo International will issue approximately 18 million shares of its common stock, $6.5 billion in cash and assume debt. The cash portion of the consideration is expected to be financed by a combination of cash, term loans, bonds ...
Read More


ENDP's price was unchanged after the transaction was announced on 05/18/15.
Investor / Buyer
Endo International plc
Creditor / Lender
TPG Biotechnology Partners IV, L.P.
TPG Global, LLC
Financial Advisor
JPMorgan Chase & Co.
Legal Advisor
Ropes & Gray LLP
 
Announced 03/11/15
14.17B for Salix Pharmaceuticals Ltd.
Merger/Acquisition

Endo International plc (NasdaqGS:ENDP) agreed to acquire Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP) for $11 billion in cash and stock on March 11, 2015. Under this agreement Endo will acquire all of the outstanding shares of Salix common stock for per share consideration with the exchange ratio of 1.4607 and $45 payable in cash. The proposal is a 'superior proposal' to Valeant's offer. Pursuant to the transaction, one seat on the Board of Directors of the combined company ...
Read More


ENDP's price was unchanged after the transaction was announced on 03/11/15.
Investor / Buyer
Endo International plc
Creditor / Lender
Deerfield International, Ltd
Deerfield Management Company, L.P.
Deerfield Partners, LP
Fidelity Management & Research Company
Franklin Resources, Inc.
HealthCor Management L.P.
Paulson & Co. Inc.
Visium Asset Management, LLC
Financial Advisor
Centerview Partners LLC
J.P. Morgan Securities LLC
Legal Advisor
Cadwalader, Wickersham & Taft LLP
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $78.70 USD -0.30

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.130.30 CHF -0.50
CR Bard Inc $197.47 USD +0.98
Edwards Lifesciences Corp $144.70 USD -0.89
Hospira Inc $89.93 USD +0.01
UCB SA €67.53 EUR -0.23
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.